1 Market Overview
1.1 Parkinsons Disease Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Parkinsons Disease Drugs Revenue by Type: 2020 Versus 2024 Versus 2031
1.2.2 Clinical
1.2.3 Experiment
1.3 Market Analysis by Application
1.3.1 Overview: Global Parkinsons Disease Drugs Revenue by Application: 2020 Versus 2024 Versus 2031
1.3.2 Treament
1.3.3 Prevention
1.4 Global Parkinsons Disease Drugs Market Size & Forecast
1.4.1 Global Parkinsons Disease Drugs Sales in Value (2020 & 2024 & 2031)
1.4.2 Global Parkinsons Disease Drugs Sales in Volume (2020-2031)
1.4.3 Global Parkinsons Disease Drugs Price (2020-2031)
1.5 Global Parkinsons Disease Drugs Production Capacity Analysis
1.5.1 Global Parkinsons Disease Drugs Total Production Capacity (2020-2031)
1.5.2 Global Parkinsons Disease Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Parkinsons Disease Drugs Market Drivers
1.6.2 Parkinsons Disease Drugs Market Restraints
1.6.3 Parkinsons Disease Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Parkinsons Disease Drugs Product and Services
2.1.4 Johnson & Johnson Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Parkinsons Disease Drugs Product and Services
2.2.4 Gilead Sciences Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.3 Pacira
2.3.1 Pacira Details
2.3.2 Pacira Major Business
2.3.3 Pacira Parkinsons Disease Drugs Product and Services
2.3.4 Pacira Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.4 Sun Pharmaceutical
2.4.1 Sun Pharmaceutical Details
2.4.2 Sun Pharmaceutical Major Business
2.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Product and Services
2.4.4 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.5 Luye Pharma
2.5.1 Luye Pharma Details
2.5.2 Luye Pharma Major Business
2.5.3 Luye Pharma Parkinsons Disease Drugs Product and Services
2.5.4 Luye Pharma Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.6 Sigma-Tau Group
2.6.1 Sigma-Tau Group Details
2.6.2 Sigma-Tau Group Major Business
2.6.3 Sigma-Tau Group Parkinsons Disease Drugs Product and Services
2.6.4 Sigma-Tau Group Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.7 Fudan-Zhangjiang
2.7.1 Fudan-Zhangjiang Details
2.7.2 Fudan-Zhangjiang Major Business
2.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Product and Services
2.7.4 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.8 Teva Pharmaceutical
2.8.1 Teva Pharmaceutical Details
2.8.2 Teva Pharmaceutical Major Business
2.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Product and Services
2.8.4 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.9 CSPC
2.9.1 CSPC Details
2.9.2 CSPC Major Business
2.9.3 CSPC Parkinsons Disease Drugs Product and Services
2.9.4 CSPC Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Parkinsons Disease Drugs Product and Services
2.10.4 Novartis Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.11 Kingond Pharm
2.11.1 Kingond Pharm Details
2.11.2 Kingond Pharm Major Business
2.11.3 Kingond Pharm Parkinsons Disease Drugs Product and Services
2.11.4 Kingond Pharm Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
3 Parkinsons Disease Drugs Breakdown Data by Manufacturer
3.1 Global Parkinsons Disease Drugs Sales in Volume by Manufacturer (2021, 2022, 2023, and 2024)
3.2 Global Parkinsons Disease Drugs Revenue by Manufacturer (2021, 2022, 2023, and 2024)
3.3 Key Manufacturer Market Position in Parkinsons Disease Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Parkinsons Disease Drugs Manufacturer Market Share in 2024
3.4.2 Top 6 Parkinsons Disease Drugs Manufacturer Market Share in 2024
3.5 Global Parkinsons Disease Drugs Production Capacity by Company: 2023 VS 2024
3.6 Manufacturer by Geography: Head Office and Parkinsons Disease Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Parkinsons Disease Drugs Market Size by Region
4.1.1 Global Parkinsons Disease Drugs Sales in Volume by Region (2020-2031)
4.1.2 Global Parkinsons Disease Drugs Revenue by Region (2020-2031)
4.2 North America Parkinsons Disease Drugs Revenue (2020-2031)
4.3 Europe Parkinsons Disease Drugs Revenue (2020-2031)
4.4 Asia-Pacific Parkinsons Disease Drugs Revenue (2020-2031)
4.5 South America Parkinsons Disease Drugs Revenue (2020-2031)
4.6 Middle East and Africa Parkinsons Disease Drugs Revenue (2020-2031)
5 Market Segment by Type
5.1 Global Parkinsons Disease Drugs Sales in Volume by Type (2020-2031)
5.2 Global Parkinsons Disease Drugs Revenue by Type (2020-2031)
5.3 Global Parkinsons Disease Drugs Price by Type (2020-2031)
6 Market Segment by Application
6.1 Global Parkinsons Disease Drugs Sales in Volume by Application (2020-2031)
6.2 Global Parkinsons Disease Drugs Revenue by Application (2020-2031)
6.3 Global Parkinsons Disease Drugs Price by Application (2020-2031)
7 North America by Country, by Type, and by Application
7.1 North America Parkinsons Disease Drugs Sales by Type (2020-2031)
7.2 North America Parkinsons Disease Drugs Sales by Application (2020-2031)
7.3 North America Parkinsons Disease Drugs Market Size by Country
7.3.1 North America Parkinsons Disease Drugs Sales in Volume by Country (2020-2031)
7.3.2 North America Parkinsons Disease Drugs Revenue by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe by Country, by Type, and by Application
8.1 Europe Parkinsons Disease Drugs Sales by Type (2020-2031)
8.2 Europe Parkinsons Disease Drugs Sales by Application (2020-2031)
8.3 Europe Parkinsons Disease Drugs Market Size by Country
8.3.1 Europe Parkinsons Disease Drugs Sales in Volume by Country (2020-2031)
8.3.2 Europe Parkinsons Disease Drugs Revenue by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Parkinsons Disease Drugs Sales by Type (2020-2031)
9.2 Asia-Pacific Parkinsons Disease Drugs Sales by Application (2020-2031)
9.3 Asia-Pacific Parkinsons Disease Drugs Market Size by Region
9.3.1 Asia-Pacific Parkinsons Disease Drugs Sales in Volume by Region (2020-2031)
9.3.2 Asia-Pacific Parkinsons Disease Drugs Revenue by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America by Region, by Type, and by Application
10.1 South America Parkinsons Disease Drugs Sales by Type (2020-2031)
10.2 South America Parkinsons Disease Drugs Sales by Application (2020-2031)
10.3 South America Parkinsons Disease Drugs Market Size by Country
10.3.1 South America Parkinsons Disease Drugs Sales in Volume by Country (2020-2031)
10.3.2 South America Parkinsons Disease Drugs Revenue by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Parkinsons Disease Drugs Sales by Type (2020-2031)
11.2 Middle East & Africa Parkinsons Disease Drugs Sales by Application (2020-2031)
11.3 Middle East & Africa Parkinsons Disease Drugs Market Size by Country
11.3.1 Middle East & Africa Parkinsons Disease Drugs Sales in Volume by Country (2020-2031)
11.3.2 Middle East & Africa Parkinsons Disease Drugs Revenue by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Raw Material and Industry Chain
12.1 Raw Material of Parkinsons Disease Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Parkinsons Disease Drugs
12.3 Parkinsons Disease Drugs Production Process
12.4 Parkinsons Disease Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Parkinsons Disease Drugs Typical Distributors
13.3 Parkinsons Disease Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Parkinsons Disease Drugs Revenue by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Parkinsons Disease Drugs Revenue by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 4. Johnson & Johnson Major Business
Table 5. Johnson & Johnson Parkinsons Disease Drugs Product and Services
Table 6. Johnson & Johnson Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 7. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 8. Gilead Sciences Major Business
Table 9. Gilead Sciences Parkinsons Disease Drugs Product and Services
Table 10. Gilead Sciences Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 11. Pacira Basic Information, Manufacturing Base and Competitors
Table 12. Pacira Major Business
Table 13. Pacira Parkinsons Disease Drugs Product and Services
Table 14. Pacira Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 15. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 16. Sun Pharmaceutical Major Business
Table 17. Sun Pharmaceutical Parkinsons Disease Drugs Product and Services
Table 18. Sun Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 19. Luye Pharma Basic Information, Manufacturing Base and Competitors
Table 20. Luye Pharma Major Business
Table 21. Luye Pharma Parkinsons Disease Drugs Product and Services
Table 22. Luye Pharma Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 23. Sigma-Tau Group Basic Information, Manufacturing Base and Competitors
Table 24. Sigma-Tau Group Major Business
Table 25. Sigma-Tau Group Parkinsons Disease Drugs Product and Services
Table 26. Sigma-Tau Group Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 27. Fudan-Zhangjiang Basic Information, Manufacturing Base and Competitors
Table 28. Fudan-Zhangjiang Major Business
Table 29. Fudan-Zhangjiang Parkinsons Disease Drugs Product and Services
Table 30. Fudan-Zhangjiang Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 31. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 32. Teva Pharmaceutical Major Business
Table 33. Teva Pharmaceutical Parkinsons Disease Drugs Product and Services
Table 34. Teva Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 35. CSPC Basic Information, Manufacturing Base and Competitors
Table 36. CSPC Major Business
Table 37. CSPC Parkinsons Disease Drugs Product and Services
Table 38. CSPC Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 39. Novartis Basic Information, Manufacturing Base and Competitors
Table 40. Novartis Major Business
Table 41. Novartis Parkinsons Disease Drugs Product and Services
Table 42. Novartis Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 43. Kingond Pharm Basic Information, Manufacturing Base and Competitors
Table 44. Kingond Pharm Major Business
Table 45. Kingond Pharm Parkinsons Disease Drugs Product and Services
Table 46. Kingond Pharm Parkinsons Disease Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 47. Global Parkinsons Disease Drugs Sales by Manufacturer (2021, 2022, 2023, and 2024) & (K Units)
Table 48. Global Parkinsons Disease Drugs Revenue by Manufacturer (2021, 2022, 2023, and 2024) & (USD Million)
Table 49. Market Position of Manufacturers in Parkinsons Disease Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 50. Global Parkinsons Disease Drugs Production Capacity by Company, (K Units): 2023 VS 2024
Table 51. Head Office and Parkinsons Disease Drugs Production Site of Key Manufacturer
Table 52. Parkinsons Disease Drugs New Entrant and Capacity Expansion Plans
Table 53. Parkinsons Disease Drugs Mergers & Acquisitions in the Past Five Years
Table 54. Global Parkinsons Disease Drugs Sales by Region (2020-2024) & (K Units)
Table 55. Global Parkinsons Disease Drugs Sales by Region (2025-2031) & (K Units)
Table 56. Global Parkinsons Disease Drugs Revenue by Region (2020-2024) & (USD Million)
Table 57. Global Parkinsons Disease Drugs Revenue by Region (2025-2031) & (USD Million)
Table 58. Global Parkinsons Disease Drugs Sales by Type (2020-2024) & (K Units)
Table 59. Global Parkinsons Disease Drugs Sales by Type (2025-2031) & (K Units)
Table 60. Global Parkinsons Disease Drugs Revenue by Type (2020-2024) & (USD Million)
Table 61. Global Parkinsons Disease Drugs Revenue by Type (2025-2031) & (USD Million)
Table 62. Global Parkinsons Disease Drugs Price by Type (2020-2024) & (USD/Unit)
Table 63. Global Parkinsons Disease Drugs Price by Type (2025-2031) & (USD/Unit)
Table 64. Global Parkinsons Disease Drugs Sales by Application (2020-2024) & (K Units)
Table 65. Global Parkinsons Disease Drugs Sales by Application (2025-2031) & (K Units)
Table 66. Global Parkinsons Disease Drugs Revenue by Application (2020-2024) & (USD Million)
Table 67. Global Parkinsons Disease Drugs Revenue by Application (2025-2031) & (USD Million)
Table 68. Global Parkinsons Disease Drugs Price by Application (2020-2024) & (USD/Unit)
Table 69. Global Parkinsons Disease Drugs Price by Application (2025-2031) & (USD/Unit)
Table 70. North America Parkinsons Disease Drugs Sales by Country (2020-2024) & (K Units)
Table 71. North America Parkinsons Disease Drugs Sales by Country (2025-2031) & (K Units)
Table 72. North America Parkinsons Disease Drugs Revenue by Country (2020-2024) & (USD Million)
Table 73. North America Parkinsons Disease Drugs Revenue by Country (2025-2031) & (USD Million)
Table 74. North America Parkinsons Disease Drugs Sales by Type (2020-2024) & (K Units)
Table 75. North America Parkinsons Disease Drugs Sales by Type (2025-2031) & (K Units)
Table 76. North America Parkinsons Disease Drugs Sales by Application (2020-2024) & (K Units)
Table 77. North America Parkinsons Disease Drugs Sales by Application (2025-2031) & (K Units)
Table 78. Europe Parkinsons Disease Drugs Sales by Country (2020-2024) & (K Units)
Table 79. Europe Parkinsons Disease Drugs Sales by Country (2025-2031) & (K Units)
Table 80. Europe Parkinsons Disease Drugs Revenue by Country (2020-2024) & (USD Million)
Table 81. Europe Parkinsons Disease Drugs Revenue by Country (2025-2031) & (USD Million)
Table 82. Europe Parkinsons Disease Drugs Sales by Type (2020-2024) & (K Units)
Table 83. Europe Parkinsons Disease Drugs Sales by Type (2025-2031) & (K Units)
Table 84. Europe Parkinsons Disease Drugs Sales by Application (2020-2024) & (K Units)
Table 85. Europe Parkinsons Disease Drugs Sales by Application (2025-2031) & (K Units)
Table 86. Asia-Pacific Parkinsons Disease Drugs Sales by Region (2020-2024) & (K Units)
Table 87. Asia-Pacific Parkinsons Disease Drugs Sales by Region (2025-2031) & (K Units)
Table 88. Asia-Pacific Parkinsons Disease Drugs Revenue by Region (2020-2024) & (USD Million)
Table 89. Asia-Pacific Parkinsons Disease Drugs Revenue by Region (2025-2031) & (USD Million)
Table 90. Asia-Pacific Parkinsons Disease Drugs Sales by Type (2020-2024) & (K Units)
Table 91. Asia-Pacific Parkinsons Disease Drugs Sales by Type (2025-2031) & (K Units)
Table 92. Asia-Pacific Parkinsons Disease Drugs Sales by Application (2020-2024) & (K Units)
Table 93. Asia-Pacific Parkinsons Disease Drugs Sales by Application (2025-2031) & (K Units)
Table 94. South America Parkinsons Disease Drugs Sales by Country (2020-2024) & (K Units)
Table 95. South America Parkinsons Disease Drugs Sales by Country (2025-2031) & (K Units)
Table 96. South America Parkinsons Disease Drugs Revenue by Country (2020-2024) & (USD Million)
Table 97. South America Parkinsons Disease Drugs Revenue by Country (2025-2031) & (USD Million)
Table 98. South America Parkinsons Disease Drugs Sales by Type (2020-2024) & (K Units)
Table 99. South America Parkinsons Disease Drugs Sales by Type (2025-2031) & (K Units)
Table 100. South America Parkinsons Disease Drugs Sales by Application (2020-2024) & (K Units)
Table 101. South America Parkinsons Disease Drugs Sales by Application (2025-2031) & (K Units)
Table 102. Middle East & Africa Parkinsons Disease Drugs Sales by Region (2020-2024) & (K Units)
Table 103. Middle East & Africa Parkinsons Disease Drugs Sales by Region (2025-2031) & (K Units)
Table 104. Middle East & Africa Parkinsons Disease Drugs Revenue by Region (2020-2024) & (USD Million)
Table 105. Middle East & Africa Parkinsons Disease Drugs Revenue by Region (2025-2031) & (USD Million)
Table 106. Middle East & Africa Parkinsons Disease Drugs Sales by Type (2020-2024) & (K Units)
Table 107. Middle East & Africa Parkinsons Disease Drugs Sales by Type (2025-2031) & (K Units)
Table 108. Middle East & Africa Parkinsons Disease Drugs Sales by Application (2020-2024) & (K Units)
Table 109. Middle East & Africa Parkinsons Disease Drugs Sales by Application (2025-2031) & (K Units)
Table 110. Parkinsons Disease Drugs Raw Material
Table 111. Key Manufacturers of Parkinsons Disease Drugs Raw Materials
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Parkinsons Disease Drugs Typical Distributors
Table 115. Parkinsons Disease Drugs Typical Customers
List of Figures
Figure 1. Parkinsons Disease Drugs Picture
Figure 2. Global Parkinsons Disease Drugs Revenue Market Share by Type in 2024
Figure 3. Clinical
Figure 4. Experiment
Figure 5. Global Parkinsons Disease Drugs Revenue Market Share by Application in 2024
Figure 6. Treament
Figure 7. Prevention
Figure 8. Global Parkinsons Disease Drugs Revenue, (USD Million) & (K Units): 2020 & 2024 & 2031
Figure 9. Global Parkinsons Disease Drugs Revenue and Forecast (2020-2031) & (USD Million)
Figure 10. Global Parkinsons Disease Drugs Sales (2020-2031) & (K Units)
Figure 11. Global Parkinsons Disease Drugs Price (2020-2031) & (USD/Unit)
Figure 12. Global Parkinsons Disease Drugs Production Capacity (2020-2031) & (K Units)
Figure 13. Global Parkinsons Disease Drugs Production Capacity by Geographic Region: 2024 VS 2031
Figure 14. Parkinsons Disease Drugs Market Drivers
Figure 15. Parkinsons Disease Drugs Market Restraints
Figure 16. Parkinsons Disease Drugs Market Trends
Figure 17. Global Parkinsons Disease Drugs Sales Market Share by Manufacturer in 2024
Figure 18. Global Parkinsons Disease Drugs Revenue Market Share by Manufacturer in 2024
Figure 19. Parkinsons Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 20. Top 3 Parkinsons Disease Drugs Manufacturer (Revenue) Market Share in 2024
Figure 21. Top 6 Parkinsons Disease Drugs Manufacturer (Revenue) Market Share in 2024
Figure 22. Global Parkinsons Disease Drugs Sales Market Share by Region (2020-2031)
Figure 23. Global Parkinsons Disease Drugs Revenue Market Share by Region (2020-2031)
Figure 24. North America Parkinsons Disease Drugs Revenue (2020-2031) & (USD Million)
Figure 25. Europe Parkinsons Disease Drugs Revenue (2020-2031) & (USD Million)
Figure 26. Asia-Pacific Parkinsons Disease Drugs Revenue (2020-2031) & (USD Million)
Figure 27. South America Parkinsons Disease Drugs Revenue (2020-2031) & (USD Million)
Figure 28. Middle East & Africa Parkinsons Disease Drugs Revenue (2020-2031) & (USD Million)
Figure 29. Global Parkinsons Disease Drugs Sales Market Share by Type (2020-2031)
Figure 30. Global Parkinsons Disease Drugs Revenue Market Share by Type (2020-2031)
Figure 31. Global Parkinsons Disease Drugs Price by Type (2020-2031) & (USD/Unit)
Figure 32. Global Parkinsons Disease Drugs Sales Market Share by Application (2020-2031)
Figure 33. Global Parkinsons Disease Drugs Revenue Market Share by Application (2020-2031)
Figure 34. Global Parkinsons Disease Drugs Price by Application (2020-2031) & (USD/Unit)
Figure 35. North America Parkinsons Disease Drugs Sales Market Share by Type (2020-2031)
Figure 36. North America Parkinsons Disease Drugs Sales Market Share by Application (2020-2031)
Figure 37. North America Parkinsons Disease Drugs Sales Market Share by Country (2020-2031)
Figure 38. North America Parkinsons Disease Drugs Revenue Market Share by Country (2020-2031)
Figure 39. United States Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 40. Canada Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 41. Mexico Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 42. Europe Parkinsons Disease Drugs Sales Market Share by Type (2020-2031)
Figure 43. Europe Parkinsons Disease Drugs Sales Market Share by Application (2020-2031)
Figure 44. Europe Parkinsons Disease Drugs Sales Market Share by Country (2020-2031)
Figure 45. Europe Parkinsons Disease Drugs Revenue Market Share by Country (2020-2031)
Figure 46. Germany Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 47. France Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 48. United Kingdom Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 49. Russia Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 50. Italy Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Parkinsons Disease Drugs Sales Market Share by Region (2020-2031)
Figure 52. Asia-Pacific Parkinsons Disease Drugs Sales Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Parkinsons Disease Drugs Sales Market Share by Region (2020-2031)
Figure 54. Asia-Pacific Parkinsons Disease Drugs Revenue Market Share by Region (2020-2031)
Figure 55. China Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 56. Japan Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 57. Korea Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 58. India Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 59. Southeast Asia Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 60. Australia Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 61. South America Parkinsons Disease Drugs Sales Market Share by Type (2020-2031)
Figure 62. South America Parkinsons Disease Drugs Sales Market Share by Application (2020-2031)
Figure 63. South America Parkinsons Disease Drugs Sales Market Share by Country (2020-2031)
Figure 64. South America Parkinsons Disease Drugs Revenue Market Share by Country (2020-2031)
Figure 65. Brazil Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 66. Argentina Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 67. Middle East & Africa Parkinsons Disease Drugs Sales Market Share by Type (2020-2031)
Figure 68. Middle East & Africa Parkinsons Disease Drugs Sales Market Share by Application (2020-2031)
Figure 69. Middle East & Africa Parkinsons Disease Drugs Sales Market Share by Region (2020-2031)
Figure 70. Middle East & Africa Parkinsons Disease Drugs Revenue Market Share by Region (2020-2031)
Figure 71. Turkey Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 72. Egypt Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 73. Saudi Arabia Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 74. South Africa Parkinsons Disease Drugs Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Parkinsons Disease Drugs in 2024
Figure 76. Manufacturing Process Analysis of Parkinsons Disease Drugs
Figure 77. Parkinsons Disease Drugs Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source

※参考情報 パーキンソン病は、中枢神経系に影響を及ぼす進行性の神経変性疾患であり、主に運動機能に 장애を引き起こします。この病気は、脳内のドーパミンを生成する神経細胞が損傷または死滅することによって発症します。ドーパミンは、神経細胞間の信号伝達を調整し、運動のスムーズな実行を助ける重要な神経伝達物質です。パーキンソン病の主な症状には、震え、硬直、動作の遅延、そして姿勢の不安定があります。これらの症状は患者の生活の質を著しく低下させることがあります。 パーキンソン病の治療は症状の緩和を目的としており、いくつかの異なる薬剤が利用されています。これらの治療薬は、主にドーパミンの不足を補うことを目的としていますが、他にも様々な作用機序を持つ薬剤があります。ここでは、パーキンソン病の治療薬の概念について、定義、特徴、種類、用途、そして関連技術を詳しく説明します。 まず、パーキンソン病治療薬の定義について触れていきます。パーキンソン病治療薬とは、パーキンソン病の症状を緩和し、患者のQOL（Quality of Life）を改善するために用いられる医薬品のことを指します。これらの薬剤は、ドーパミンの作用を模倣する、またはドーパミンの働きを高めることによって、脳内の神経伝達のバランスを整える働きがあります。 次に、パーキンソン病治療薬の特徴について説明します。これらの薬剤は、通常、病気の進行に応じて異なる段階で処方されます。初期の段階では、症状が軽度である場合、より軽い薬剤が選択されることが一般的です。しかし、病気が進行するにつれて、症状が強まるため、より強力な薬剤が必要になることがあります。また、パーキンソン病治療薬は、単剤療法で効果が不十分な場合には、複数の薬剤を組み合わせて使用することもあります。 パーキンソン病治療薬には、いくつかの種類があります。代表的なものは、ドーパミン前駆体薬、ドーパミン受容体作動薬、MAO-B阻害薬、COMT阻害薬などです。 ドーパミン前駆体薬は、通常、レボドパ（L-DOPA）が最も代表的な薬剤です。レボドパは体内でドーパミンに変換され、脳内でのドーパミンレベルを上昇させる作用があります。レボドパは一般的に、他の薬剤と組み合わせて処方されることがあります。レボドパは非常に効果的ですが、長期間使用することで運動障害（運動波動）や異常運動が現れることがあります。 ドーパミン受容体作動薬は、ドーパミンの受容体に直接作用して、ドーパミンの効果を模倣する薬剤です。これにより、運動機能の改善が期待されます。具体的な薬剤として、ロピニロール、プラミペキソールなどがあり、効果を示すとともに、レボドパの併用においても使用されます。 MAO-B阻害薬は、脳内のドーパミンの分解を防ぐタイプの薬剤です。モニアゼパムなどがこのカテゴリに属し、ドーパミンの効果を持続させることで、パーキンソン病の症状を軽減することが期待されます。 COMT阻害薬は、レボドパの効果を高めるために使用されます。ケトコナゾールやエンタカポンなどがこのグループに分類され、レボドパと併用することによって、効果の持続時間を延ばすことができます。 パーキンソン病治療薬の用途は、主に病状の改善に焦点を当てています。これらの薬剤は、運動機能の改善、日常生活の質の向上、そして最終的には患者が自立して生活できるようにすることを目的としています。しかし、これらの薬剤には副作用も存在し、特に長期使用に伴う副作用は注意が必要です。患者によって影響の出方は異なるため、治療計画は個別化されることが重要です。 さらに、関連技術も注目されています。最近では、デジタルヘルス技術がパーキンソン病の管理においても取り入れられています。ウェアラブルデバイスやアプリケーションを使用することで、患者の症状や薬の効果をリアルタイムでモニタリングする仕組みが増えてきています。これらの技術により、医師は患者の状態を的確に把握し、治療方針を調整することが可能になります。また、早期発見や治療、そして症状の自動評価などが進められています。 最後に、パーキンソン病治療薬には、今後の研究や開発が期待されています。新しい治療法としては、遺伝子治療や幹細胞治療、さらに新たな作用機序を持つ薬剤の開発が進められており、今後の進展が注目されています。パーキンソン病のメカニズムを深く理解することによって、より効果的な治療法が見つかることが望まれています。 以上のように、パーキンソン病治療薬は、症状の緩和や患者の生活の質を向上させるための重要な役割を果たしています。多様な種類の薬剤が存在し、個々の患者に応じた治療が求められるこの病気において、今後の研究や技術の進展がますます重要になっていくことでしょう。これらの治療薬と関連技術の発展により、多くの患者がより良い生活を送れることを期待し、医療従事者や研究者が一丸となって取り組む必要があります。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/